Treatment of uveitis with methotrexate.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000328:Adult; D000505:Alopecia / Q000139:chemically induced; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D002738:Chloroquine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea; D009879:Ophthalmia, Sympathetic / Q000188:drug therapy; D011739:Pyrimethamine / Q000627:therapeutic use; D013280:Stomatitis; D014605:Uveitis / Q000188:drug therapy*; D014785:Vision, Ocular; D014839:Vomiting
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D007166:Immunosuppressive Agents; D002738:Chloroquine; D000324:Adrenocorticotropic Hormone; D007213:Indomethacin; D008727:Methotrexate; D011739:Pyrimethamine